06 April 2017
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Director Dealing and Issue of Equity
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that application has been made for 5,731 new ordinary shares of 10p each (the "New Ordinary Shares") to be admitted to trading on AIM on 13 April 2017 ("Admission").
The New Ordinary Shares have been allotted pursuant to the purchase by Michael Albin, Non-Executive Director of the Company, of New Ordinary Shares in accordance with the terms set out in the Company's announcement of 23 February 2016.
Following Admission, the total number of ordinary shares with voting rights in issue will be 68,392,588. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Enquiries:
Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer
|
Tel: +44 (0) 844 414 0452 |
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Alice Lane - Corporate Broking
WG Partners David Wilson Nigel Barnes Claes Spang
|
Tel: +44 (0) 207 220 0500
Tel: +44 (0) 203 705 9318 Tel: +44 (0) 203 705 9217
|
Media Enquiries FTI Consulting Simon Conway / Natalie Garland-Collins |
Tel: +44 (0) 203 727 1000 |
Notes to Editors
Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
a) |
Name |
Michael Albin |
||||
2. |
Reason for the Notification |
|||||
a) |
Position/status |
Non - Executive Director |
||||
b) |
Initial notification/Amendment |
|
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
Avacta Group Plc |
||||
b) |
LEI |
2138009U3EG31OPMGH36 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
a) |
Description of the Financial instrument, type of instrument |
|
||||
Identification code |
GB00BYYW9G87 |
|||||
b) |
Nature of the transaction |
|
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information: · Aggregated volume · Price |
See above |
||||
e) |
Date of the transaction |
6 April 2017 |
||||
f) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |